Q-omics provides the consensus-scored UBE2NL profile across patient tissues and cancer cell-line models. UBE2NL expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, UBE2NL is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, UBE2NL RNA expression shows 6,249 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight LIHC, COAD, and OV as cancer lineages where UBE2NL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2NL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2NL survival associations across molecular data types. UBE2NL RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2NL RNA expression–survival associations across cancer types. High UBE2NL expression shows unfavorable associations in LIHC, MESO, KICH and OV, but favorable associations in CESC and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for UBE2NL RNA expression.
This table summarizes UBE2NL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2NL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2NL shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, STAD, LUAD and LIHC. The COAD box plot shows higher UBE2NL RNA expression in tumor versus normal tissue (log2 FC = +0.190, t-test p < 0.001).
This table shows molecular features associated with UBE2NL in patient tissues and cancer cell lines. In patient samples, UBE2NL shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2NL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
